Zongliang L. Zhang

Nanobiosensing And Microfluidic Point Of Care Testing Key Laboratory Of Luzhou, Luzhou 646000, Luzhou 646000
Chengdu, 611730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

One-pot isothermal index amplification combined with molecular beacons for ultrasensitive miRNA analysis

One-pot isothermal index amplification combined with molecular beacons for ultrasensitive miRNA analysis

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: May 13, 2026

YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma.

YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma.

Journal: Journal for immunotherapy of cancer

Published: February 04, 2026

A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy.

A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy.

Journal: Journal of nanobiotechnology

Published: November 26, 2025

B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression.

B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression.

Journal: Molecular biomedicine

Published: November 14, 2025

Tumor-targeting oncolytic HSV-SUR15 enhances anti-tumor immunity in glioblastoma.

Tumor-targeting oncolytic HSV-SUR15 enhances anti-tumor immunity in glioblastoma.

Journal: International immunopharmacology

Published: June 27, 2025

A chimeric oncolytic adenovirus carried by macrophages for glioma immunotherapy.

A chimeric oncolytic adenovirus carried by macrophages for glioma immunotherapy.

Journal: Biochemical and biophysical research communications

Published: June 03, 2025

A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma.

A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma.

Journal: Journal of translational medicine

Published: June 03, 2025

Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors.

Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors.

Journal: Journal for immunotherapy of cancer

Published: May 19, 2025

Tumor immunotherapy: past, present, and future.

Tumor immunotherapy: past, present, and future.

Journal: International journal of surgery (London, England)

Published: March 31, 2025

Injectable hydrogel-mediated co-delivery of oncolytic adenovirus and melphalan for retinoblastoma control and vision preservation.

Injectable hydrogel-mediated co-delivery of oncolytic adenovirus and melphalan for retinoblastoma control and vision preservation.

Journal: Acta pharmaceutica Sinica. B

Published: March 20, 2025

A fc-engineered NKG2D × B7-H3 bispecific antibody enhances the antitumor activity by orchestrating cytotoxic lymphocytes.

A fc-engineered NKG2D × B7-H3 bispecific antibody enhances the antitumor activity by orchestrating cytotoxic lymphocytes.

Journal: International immunopharmacology

Published: January 01, 2025

Myeloid-derived suppressor cell-targeted virus-like particles synergistically activate innate immune response for cancer immunotherapy.

Myeloid-derived suppressor cell-targeted virus-like particles synergistically activate innate immune response for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: October 24, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026